>>> US After Hours Summary: AGYS +14.2% sharply higher on earnings; NOMD +1.1%

After Hours Summary: AGYS +14.2% sharply higher on earnings; NOMD +1.1% on insider purchases; XP -4.3% lower on earnings

After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AGYS +14.2%

Companies trading higher in after hours in reaction to news: INFU +3.7% (authorizes new $20 mln stock repurchase program), WVE +3.6% (update on RestorAATion-2 Trial), NRGV +2.4% (to delay 10-Q), TLX +2.1% (completes enrollment for IPAX-2 study of TLX101-Tx), GSIT +1.7% (awarded Phase I of a Smart City project by the Hsinchu County government in Taiwan), MSCI +1.2% (Chairman and CEO Henry Fernandez bought 4,000 shares at $559.40-565.17 worth ~$2.25 mln), NOMD +1.1% (discloses share purchases by CEO and CFO), CGEN +1% (files for $400 mln mixed securities shelf offering), DOW +0.9% (NRC completes EA for DOW and XE Construction Permit Application), LUNR +0.9% (two prime lunar reconnaissance contracts), DRS +0.7% (launches Tenum 640 Orbit), SSRM +0.7% (to sell 20% equity interest in Hod Maden), RGLD +0.7% (restructures HOD Maden project interests), ANTA +0.7% (strategic expansion into AI infrastructure), LMB +0.6% (appoints new COO), BLDR +0.5% (COO to retire; names successor), MDLN +0.5% (deploys new AutoStore installation at distribution center), EVTL +0.4% (stock offering by selling shareholders), T +0.1% (on track to achieve 2026 and multi-year guidance)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: XP -4.3% (also appoints new CFO; also authorizes R$1.0 bln share repurchase program)

Companies trading lower in after hours in reaction to news: AKAM -2.8% (convertible senior notes offering), ICHR -0.6% (files mixed securities shelf offering), CTRE -0.2% (common stock offering), TSLA -0.2% (Elon Musk says he will file an appeal with the Ninth Circuit regarding the OpenAI verdict in X post), CGEM -0.1% (to present initial clinical data for CLN-978 in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus